{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.3.2.3 Progressive Disease', 'PD of nontarget lesions is defined as unequivocal progression of existing nontarget lesions or', 'the appearance of 1 or more new lesions.', '5.3.3', 'Evaluation of Time Point Response', 'The overall response status at each time point for subjects with measurable disease at', 'baseline will be reported according to the table in [Appendix 12.7]', '.', '5.4', 'Pharmacokinetic Assessment', 'PK samples will be collected during the treatment period and at the post-treatment follow-up', 'visit for subjects who receive EV for determination of ADC and MMAE concentrations. If a', 'subject presents to clinic but does not get dosed, a predose PK sample collection should be', 'performed.', 'Blood samples (7 mL/sample) for pharmacokinetic analyses should be collected at the time', 'points indicated in the Schedule of Assessments Table 1)', 'Blood samples should be collected', 'via a peripherally placed intravenous cannula or by direct venipuncture.', 'Blood should not be drawn from the arm or port used for study drug infusion.', 'Bioanalysis of TAb, ADC and MMAE in serum or plasma will be performed using validated', 'methods at bioanalytical laboratories specified by the sponsor.', '5.5', 'Safety Assessment', '5.5.1', 'Vital Signs', 'Vital signs, including systolic and diastolic blood pressures (mmHg), radial pulse rate', '(beats/minute) and temperature will be obtained according to the Schedule of Assessments', 'Table 1 and recorded. All vital sign measures will be obtained with the subject in the sitting', 'or supine position.', 'If clinically significant vital sign changes from Baseline (pretreatment) are noted, the changes', 'will be documented as AEs on the AE page of the eCRF. Clinical significance will be defined', 'as a variation in vital signs that has medical relevance as deemed by the investigator that could', 'result in an alteration in medical care. The investigator will continue to monitor the subject', 'until the parameter returns to Grade 1, or to the Baseline (pretreatment) value, or until the', 'investigator determines that follow up is no longer medically necessary.', '5.5.2 Adverse Events', 'See [Section 5.6 Adverse Events and Other Safety Aspects] for information regarding AE', 'collection and data handling.', '5.5.2.1 Adverse Events of Possible Hepatic Origin', 'See [Appendix 12.2 Liver Safety Monitoring and Assessment for detailed information on', 'liver abnormalities, monitoring and assessment, if the AE for a subject enrolled in a study', '14 Sep 2020', 'Astellas', 'Page 69 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'and receiving study drug is accompanied by increases in Liver Function Tests value ([LFT],', 'e.g., AST, ALT, bilirubin, etc.) or is suspected to be due to hepatic dysfunction.', 'Subjects with AEs of hepatic origin accompanied by LFT abnormalities should be carefully', 'monitored.', '5.5.3 Laboratory Assessments', 'Below is a table of the laboratory tests that will be performed during the conduct of the study.', 'See Schedule of Assessments for study visit collection dates.', 'Biochemistry', 'Sodium (Na), Magnesium (Mg), Potassium (K), Calcium (Ca), Chloride (CI),', 'Phosphate (P), Serum Creatinine, Glucose (GI), Blood Urea Nitrogen (BUN),', 'ALP, AST, ALT, Lactate Dehydrogenase (LDH), Bilirubin (total and direct),', 'Total Protein (TP), Albumin (Alb), Bicarbonate (HCO3), Amylase, Lipase,', 'Uric Acid, Hemoglobin Alc (screening only), Serum HCG for female subjects', 'of childbearing potential', 'Hematology', 'Red Blood Cell Count (RBC), Hematocrit (Hct), Hemoglobin (Hgb), Platelets,', 'white blood cell count WBC)/differential (Neutrophils, Eosinophils,', 'Basophils, Lymphocytes, Monocytes),', 'Urinalysis', 'Pregnancy', 'HbA1c', 'Laboratory tests will be performed predose according to the Schedule of Assessments and', 'sent to a central laboratory for analysis. All screening labs must be sent to the central', 'laboratory, but local laboratory results may be used to determine eligibility if the screening', 'results from the central laboratory are not available in time for planned randomization. In the', 'event that the central laboratory results received after randomization are not within eligibility', 'parameters, the subject will still be considered eligible if local labs met the eligibility criteria', 'and will not be considered a protocol deviation. Local laboratory results that support', 'eligibility and dosing decisions must be entered into the clinical database. If local laboratory', 'is to be used to support dosing decisions, local laboratory tests will include complete blood', 'count with differential, glucose, serum creatinine, ALT and AST. In case of multiple', 'laboratory data within this period, the most recent data should be used. Laboratory', 'assessments collected outside of -7 days of randomization should be repeated. Additional', 'assessments may be done centrally or locally to monitor AEs or as required by dose', 'modification requirements.', 'Assessment of creatinine clearance or estimation of GFR per institutional guidelines should', 'be performed prior to administration of vinflunine and EV as recommended in [Section 5.1.2', 'Increase or Reduction in Dose of the Study Drug(s)].', 'Additional laboratory tests should be performed according to institutional standard of care.', 'Clinical significance of out-of-range laboratory findings is to be determined and documented', 'by the investigator/sub-investigator who is a qualified physician.', '14 Sep 2020', 'Astellas', 'Page 70 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}